| Aug 16 |
Looking Into Aditxt's Recent Short Interest
|
| Aug 14 |
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
|
| Aug 13 |
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
|
| Aug 7 |
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
|
| Jul 25 |
Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
|
| Jul 25 |
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
|
| Jul 25 |
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
|
| Jul 23 |
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
|
| Jul 18 |
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
|
| Jul 17 |
Dow Jumps 200 Points; Synchrony Financial Posts Upbeat Earnings
|
